Abstract: Personalized treatment plan generation from an inference engine of a system. The system may receive or retrieve data from a plurality of sources and parse the data to generate individual data fields defining characteristics of a patient. The inference engine may process the contents of the individual data fields in relation to rule blocks suggesting certain treatment actions and combinations thereof in response to satisfied conditions. The inference engine may implement machine learning to refine rule blocks and improve functioning of the system to optimize healthcare.

Abstract: Personalized treatment plan generation from an inference engine of a system. The system may receive or retrieve data from a plurality of sources and parse the data to generate individual data fields defining characteristics of a patient. The inference engine may process the contents of the individual data fields in relation to rule blocks suggesting certain treatment actions and combinations thereof in response to satisfied conditions. The inference engine may implement machine learning to refine rule blocks and improve functioning of the system to optimize healthcare.

Abstract: The present disclosure includes methods for the prediction of outcome in breast cancer where EGFR/ErbB family members are over expressed and the benefit of treatment with an anti-ErbB antibody. More specifically, the present invention relates the use of the mRNA expression level of a C8A, OR56A1, or PRR20C biomarker compared to a reference expression level for providing information regarding the benefit of treatment with a HER2 antibody, such as trastuzumab, in HER2+ breast cancer.

Abstract: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer.

Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.

Abstract: Described herein are methods for predicting the recurrence, progression, and metastatic potential of a prostate cancer in a subject. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of FOXO1A, SOX9, CLNS1A, PTGDS, XPO1, LETMD1, RAD23B, ABCC3, APC, CHES1, EDNRA, FRZB, HSPG2, and TMPRSS2_ETV1 FUSION. The method can further comprise detecting in a sample from a subject one or more biomarkers selected from the group consisting of miR-103, miR-339, miR-183, miR-182, miR-136, and miR-221. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.

Abstract: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer.

Abstract: The present invention relates to a method for prognosing or classifying cancer subtypes in a subject with breast cancer. Methods and biomarkers are disclosed that are useful for prognosing or classifying ESR1, PGR and ERBB2 breast cancer subtypes.

Abstract: The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.

Abstract: The present invention relates generally to the use of Insulin like Growth Factor Binding Protein-3 (IGFBP-3) as an anti-neoplastic agent. More particularly, the invention relates to the use of IGFBP-3 in the treatment of patients with lung cancer.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anesthetics.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anticoagulants.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiviral agents.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C9 (CYP 2C9). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C9 (CYP 2C9) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs metabolized by CYP 2C9 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antibiotic agents.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antihistamines.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anxiolitic agents.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antipsychotic agents.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.